
AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …

Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …

In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …

Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …

LEO Pharma has revealed new Phase 2b at the European Academy of Dermatology and Venereology (EADV) Virtual 2020 Virtual Congress …

The European Commission (EC) has given approval to Insmed Incorporated’s Arikayce (liposomal 590mg nebuliser dispersion) for the treatment of nontuberculous …

The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its …

The latest monthly edition of Pharmafocus is available to read for free online now!

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …

Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …

Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it …

New virtual reality software allows researchers to “walk” inside cells and analyse them up close in order to better understand …